March 01, 2015 2:50 AM ET


Company Overview of NovaDigm Therapeutics, Inc.

Company Overview

NovaDigm Therapeutics, Inc. develops vaccines to protect patients from fungal and bacterial infections. Its products include NDV-3, a vaccine to demonstrate preclinical efficacy in reducing the severity of disease caused by fungal and bacterial pathogens; and Als3, an antigen vaccine, which provides protection against systemic and mucosal candidal infections. NovaDigm Therapeutics, Inc. was founded in 2005 and is based in Grand Forks, North Dakota.

4201 James Ray Drive

REAC 1 Building

Suite 2200

Grand Forks, ND 58202

United States

Founded in 2005





Key Executives for NovaDigm Therapeutics, Inc.

Chief Executive Officer and Director
Vice President of Corporate Development
Scientific Founder
Scientific Founder
Scientific Founder
Compensation as of Fiscal Year 2014.

NovaDigm Therapeutics, Inc. Key Developments

NovaDigm Therapeutics Initiates Phase 1b/2a Clinical Trial with NDV-3 Vaccine in Recurrent Vulvovaginal Candidiasis (RVVC)

NovaDigm Therapeutics announced the initiation of a Phase 1b/2a clinical trial to evaluate its NDV-3 vaccine in preventing episodes of vulvovaginal candidiasis (VVC) in patients with recurrent VVC (RVVC). The trial is a multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and efficacy of NDV-3. NDV-3 is a vaccine being developed for the treatment and prevention of infections caused by the fungus Candida and the bacterium Staphylococcus aureus (including methicillin-resistant Staphylococcus aureus, or MRSA). NDV-3 is the first vaccine to demonstrate preclinical 'cross-kingdom' protective efficacy against both fungal and bacterial pathogens. The Phase 1b/2a trial will enroll 189 patients at multiple centers in the United States. The objectives of the study are to estimate the effect of a single, intramuscularly-administered dose of NDV-3, as compared to placebo, by evaluating safety and tolerability, as well as humoral and cellular immune responses, over a 12-month period. In addition to these objectives, the study will summarize recurrence of VVC over both a six- and 12-month period, time-to-onset of first VVC episode and severity of subsequent VVC episodes. A summary of the study can be found on the United States National Institutes of Health website, identifier number NCT01926028.

Novadigm Presents at World Vaccine Congress Washington 2013, Apr-17-2013 11:35 AM

Novadigm Presents at World Vaccine Congress Washington 2013, Apr-17-2013 11:35 AM. Venue: Gaylord National Hotel and Convention Center, Washington, District Of Columbia, United States. Speakers: Timothy Cooke, Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
A-FAM LLC Inc. United States
Essentialis, Inc. United States
Lung Therapeutics, Inc. United States
Actient Pharmaceuticals, LLC United States
Health Plus Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NovaDigm Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at